- 米国企業
- Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plcJAZZ
| 2011年
12月31日 | 2012年
12月31日 | 2013年
12月31日 | 2014年
12月31日 | 2015年
12月31日 | 2016年
12月31日 | 2017年
12月31日 | 2018年
12月31日 | 2019年
12月31日 | 2020年
12月31日 | 2021年
12月31日 | 2022年
12月31日 | 2023年
12月31日 |
|---|
| Net income (loss) | 125 | 289 | 216 | 58 | 330 | 397 | 488 | 447 | 523 | 239 | -330 | -224 | 415 |
|---|
| Intangible asset amortization | 7 | 73 | 79 | 127 | 98 | 102 | 152 | 201 | 355 | 260 | 526 | 599 | 608 |
|---|
| Acquired in-process research and development | - | - | - | 203 | - | 24 | 85 | - | 110 | 251 | - | 444 | 19 |
|---|
| Share-based compensation | 21 | 23 | 45 | 70 | 92 | 99 | 107 | 102 | 111 | 121 | 189 | 222 | 227 |
|---|
| Inventory Step-Up Value Adjustment | - | - | - | - | - | - | - | - | - | - | 223 | 273 | 151 |
|---|
| Share-based compensation | 21 | 23 | 45 | 70 | 92 | 99 | 107 | 102 | 111 | 121 | 189 | 222 | 227 |
|---|
| Tangible Asset Impairment Charges | - | - | - | - | - | - | - | - | - | - | - | - | 61 |
|---|
| Asset Impairment Charges | - | - | - | 39 | 32 | - | - | 43 | - | 136 | - | 134 | - |
|---|
| Depreciation | 0 | 1 | 3 | 7 | 10 | 12 | 13 | 15 | 15 | 19 | 27 | 30 | 30 |
|---|
| Noncash Interest Expense | - | - | - | - | - | - | - | - | - | - | 93 | 38 | 22 |
|---|
| Loss on disposal of a business | - | 35 | - | - | - | - | - | - | - | - | - | -38 | - |
|---|
| Acquired in-process research and development | - | - | - | 203 | - | 24 | 85 | - | 110 | 251 | - | 444 | 19 |
|---|
| Depreciation | 0 | 1 | 3 | 7 | 10 | 12 | 13 | 15 | 15 | 19 | 27 | 30 | 30 |
|---|
| Provision for losses on accounts receivable and inventory | - | 5 | 2 | 2 | 4 | 2 | 2 | 5 | 7 | 15 | 20 | 15 | 11 |
|---|
| Provision for losses on accounts receivable and inventory | - | 5 | 2 | 2 | 4 | 2 | 2 | 5 | 7 | 15 | 20 | 15 | 11 |
|---|
| Deferred tax expense (benefit) | - | -114 | -10 | -43 | -61 | -41 | -226 | -89 | -237 | -137 | 69 | -292 | -260 |
|---|
| Other non-cash transactions | - | - | -6 | -2 | 5 | 4 | -14 | -4 | 4 | -15 | -10 | 14 | -11 |
|---|
| Intangible asset impairment charge | - | - | - | 39 | - | - | - | - | - | - | - | - | - |
|---|
| Deferred tax expense (benefit) | - | -114 | -10 | -43 | -61 | -41 | -226 | -89 | -237 | -137 | 69 | -292 | -260 |
|---|
| Loss on disposal of a business | - | 35 | - | - | - | - | - | - | - | - | - | -38 | - |
|---|
| Distributions from equity method investees | - | - | - | - | - | - | - | - | - | 5 | - | - | - |
|---|
| Other non-cash transactions | - | - | -6 | -2 | 5 | 4 | -14 | -4 | 4 | -15 | -10 | 14 | -11 |
|---|
| Accounts receivable | 12 | 5 | 49 | 55 | 25 | 26 | -12 | 40 | 92 | 39 | 93 | 90 | 52 |
|---|
| Inventories | -1 | -2 | 9 | 8 | -6 | 17 | 9 | 19 | 33 | 31 | 49 | 50 | 13 |
|---|
| Prepaid expenses and other current assets | 1 | 13 | 14 | -12 | -4 | 16 | 27 | -7 | 26 | 98 | 83 | -36 | 126 |
|---|
| Operating lease assets | - | - | - | - | - | - | - | - | -14 | -12 | -16 | -15 | -15 |
|---|
| Other non-current assets | - | - | - | 9 | 12 | -0 | -0 | 0 | 15 | -22 | -1 | 24 | 16 |
|---|
| Accounts payable | 2 | -7 | 5 | -38 | -2 | 0 | 0 | 17 | 5 | -19 | 57 | -11 | 10 |
|---|
| Accrued liabilities | 11 | -2 | 15 | 21 | 3 | 10 | -7 | 71 | -6 | 79 | 142 | 166 | -23 |
|---|
| Income taxes payable | - | 30 | -39 | 9 | -6 | 3 | 16 | -20 | 10 | 13 | -16 | -2 | 25 |
|---|
| Deferred revenue | - | - | - | - | - | - | - | -7 | -5 | -5 | -2 | -2 | -0 |
|---|
| Operating lease liabilities, less current portion | - | - | - | - | - | - | - | - | -6 | -12 | -16 | -16 | -17 |
|---|
| Other non-current liabilities | - | 2 | 15 | 18 | 27 | 23 | 19 | 15 | 4 | -9 | -5 | -11 | -6 |
|---|
| Net cash provided by operating activities | 152 | 250 | 284 | 406 | 532 | 591 | 693 | 799 | 776 | 900 | 779 | 1,272 | 1,092 |
|---|
| Proceeds from maturity of investments | - | - | - | - | - | - | 230 | 855 | 985 | 1,755 | 1,095 | 60 | 270 |
|---|
| Proceeds from sale of a business | - | - | - | - | 34 | - | - | - | - | - | - | 53 | - |
|---|
| Acquired in-process research and development | - | - | - | 203 | - | 24 | 85 | - | 62 | 251 | - | 444 | 19 |
|---|
| Acquisition of intangible assets | 5 | 17 | 1 | - | - | 150 | - | 111 | 81 | 113 | 18 | 25 | - |
|---|
| Purchases of property, plant and equipment | - | - | - | - | - | - | - | - | - | 15 | 28 | 29 | 24 |
|---|
| Purchases of property, plant and equipment | - | - | - | - | - | - | - | - | - | 15 | 28 | 29 | 24 |
|---|
| Acquisition of investments | - | - | - | - | - | 65 | 385 | 1,166 | 917 | 2,398 | 27 | 61 | 390 |
|---|
| Acquisition of investments | - | - | - | - | - | 65 | 385 | 1,166 | 917 | 2,398 | 27 | 61 | 390 |
|---|
| Proceeds from sale of a business | - | - | - | - | 34 | - | - | - | - | - | - | 53 | - |
|---|
| Acquired in-process research and development | - | - | - | 203 | - | 24 | 85 | - | 62 | 251 | - | 444 | 19 |
|---|
| Acquisition of intangible assets | 5 | 17 | 1 | - | - | 150 | - | 111 | 81 | 113 | 18 | 25 | - |
|---|
| Acquisition of a business, net of cash acquired | - | 543 | - | 829 | - | 1,502 | - | - | - | - | 6,235 | - | - |
|---|
| Net cash used in investing activities | -81 | -395 | -11 | -1,068 | -2 | -1,749 | -269 | -394 | -155 | -1,008 | -5,212 | -446 | -163 |
|---|
| Proceeds from employee equity incentive and purchase plans | - | - | - | - | - | 24 | 32 | 93 | 58 | 100 | 135 | 98 | 46 |
|---|
| Share repurchases | - | - | 136 | 42 | 62 | 278 | 99 | 524 | 301 | 147 | - | 0 | 270 |
|---|
| Repayments of long-term debt | 42 | 12 | 466 | 10 | 906 | 28 | 36 | 26 | 33 | 33 | 1,102 | 582 | 31 |
|---|
| Payment of employee withholding taxes related to share-based awards | - | 25 | 6 | 18 | 26 | 21 | 19 | 18 | 17 | 17 | 36 | 45 | 51 |
|---|
| Repayments of long-term debt | 42 | 12 | 466 | 10 | 906 | 28 | 36 | 26 | 33 | 33 | 1,102 | 582 | 31 |
|---|
| Share repurchases | - | - | 136 | 42 | 62 | 278 | 99 | 524 | 301 | 147 | - | 0 | 270 |
|---|
| Proceeds From Issuance Of Term Loan | - | - | - | - | - | - | - | - | - | - | 3,720 | - | - |
|---|
| Proceeds from Issuance of Senior Long-Term Debt | - | - | - | - | - | - | - | - | - | - | 1,472 | - | - |
|---|
| Payments for repurchase of Exchangeable Senior Notes, due 2021 | - | - | - | - | - | - | - | - | - | 356 | 219 | - | - |
|---|
| Proceeds from Convertible Debt | - | - | - | - | - | - | - | - | - | 981 | - | - | - |
|---|
| Net cash (used in) provided by financing activities | -33 | 449 | -24 | 713 | -214 | 541 | -409 | -479 | -294 | 528 | 3,971 | -529 | -305 |
|---|
| Proceeds from Lines of Credit | - | - | - | - | - | - | - | - | - | 500 | - | - | - |
|---|
| Repayments under revolving credit facility | - | - | - | 300 | 160 | 150 | 850 | - | - | 500 | - | - | - |
|---|
| Net cash (used in) provided by financing activities | -33 | 449 | -24 | 713 | -214 | 541 | -409 | -479 | -294 | 528 | 3,971 | -529 | -305 |
|---|
| Effect of exchange rates on cash and cash equivalents | - | - | - | - | - | - | - | - | 0 | 0 | -3 | -6 | 1 |
|---|
| Net increase (decrease) in cash and cash equivalents | - | - | - | - | - | - | - | - | 328 | 420 | -466 | 290 | 625 |
|---|
| Cash paid for interest | 2 | 14 | 18 | 32 | 40 | 40 | 45 | 43 | 43 | 42 | 138 | 271 | 333 |
|---|
| Income Taxes Paid | - | 9 | 138 | 108 | 146 | 160 | 174 | 164 | 184 | 227 | 271 | 95 | 178 |
|---|